Taking into consideration that there is a significant inter-assay heterogeneity in detecting PD-L1 in HCC, as was evident in the Blueprint-HCC study [57], further efforts are needed to standardize the measurement of PD-L1 expression in HCC to improve its consistency as a potential biomarker of the response to ICIs. The gene discussed is CD274; the disease is hepatocellular carcinoma.